These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 39063241)

  • 21. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
    Pergolizzi JV; Christo PJ; LeQuang JA; Magnusson P
    Drug Des Devel Ther; 2020; 14():1009-1025. PubMed ID: 32210534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A potential role for the gut microbiome in substance use disorders.
    Meckel KR; Kiraly DD
    Psychopharmacology (Berl); 2019 May; 236(5):1513-1530. PubMed ID: 30982128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation.
    Vijayvargiya P; Camilleri M; Vijayvargiya P; Erwin P; Murad MH
    Aliment Pharmacol Ther; 2020 Jul; 52(1):37-53. PubMed ID: 32462777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis.
    Ouyang R; Li Z; Huang S; Liu J; Huang J
    Pain Med; 2020 Nov; 21(11):3224-3232. PubMed ID: 32488259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the gut microbiome in opioid use.
    Ren M; Lotfipour S
    Behav Pharmacol; 2020 Apr; 31(2&3):113-121. PubMed ID: 31895059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management.
    Holzer P; Ahmedzai SH; Niederle N; Leyendecker P; Hopp M; Bosse B; Spohr I; Reimer K
    J Opioid Manag; 2009; 5(3):145-51. PubMed ID: 19662924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid-induced Constipation: A Review of Health-related Quality of Life, Patient Burden, Practical Clinical Considerations, and the Impact of Peripherally Acting μ-Opioid Receptor Antagonists.
    Argoff CE
    Clin J Pain; 2020 Sep; 36(9):716-722. PubMed ID: 32554978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.
    Lemaire A; Pointreau Y; Narciso B; Piloquet FX; Braniste V; Sabaté JM
    Support Care Cancer; 2021 Dec; 29(12):7577-7586. PubMed ID: 34120247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain.
    Viscusi ER
    Clin J Pain; 2019 Feb; 35(2):174-188. PubMed ID: 30289777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naloxegol to Treat Constipation in a Patient Taking Opioids for Cancer Pain: A Case Report.
    Gálvez R; Maire C; Tovar I; Vargas P
    A A Pract; 2018 Jul; 11(1):22-24. PubMed ID: 29634552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic treatment of opioid-induced constipation.
    Wang CZ; Yuan CS
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1225-7. PubMed ID: 23834367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription opioids induced microbial dysbiosis worsens severity of chronic pancreatitis and drives pain hypersensitivity.
    Kesh K; Tao J; Ghosh N; Jalodia R; Singh S; Dawra R; Roy S
    Gut Microbes; 2024; 16(1):2310291. PubMed ID: 38329115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone.
    Rauck RL
    Drugs; 2013 Aug; 73(12):1297-306. PubMed ID: 23881667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioid-induced constipation: pathophysiology, clinical consequences, and management.
    Kumar L; Barker C; Emmanuel A
    Gastroenterol Res Pract; 2014; 2014():141737. PubMed ID: 24883055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
    Jones R; Prommer E; Backstedt D
    Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid induced constipation management in orthopaedic and trauma patients: treatment and the potential of nurse-initiated management.
    Sonneborn O; Bui T
    Int J Orthop Trauma Nurs; 2019 Aug; 34():16-20. PubMed ID: 31126838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model.
    Meng J; Abu YF; Zhang Y; Zhou Y; Xie Y; Yan Y; Tao J; Ramakrishnan S; Chen C; Roy S
    Br J Pharmacol; 2023 May; 180(10):1362-1378. PubMed ID: 36562107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Opioid Therapy and Management of Side Effects Associated with Opioids].
    Nakatani T
    Gan To Kagaku Ryoho; 2017 Apr; 44(4):294-297. PubMed ID: 28428507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylnaltrexone bromide for the treatment of opioid-induced constipation.
    Mozaffari S; Nikfar S; Abdollahi M
    Expert Opin Pharmacother; 2018 Jul; 19(10):1127-1135. PubMed ID: 29979903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain.
    Zádori ZS; Király K; Al-Khrasani M; Gyires K
    Pharmacol Ther; 2023 Jan; 241():108327. PubMed ID: 36473615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.